PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification

Affiliation auteurs!!!! Error affiliation !!!!
TitrePERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification
Type de publicationJournal Article
Year of Publication2021
AuteursTabernero J., Bekaii-Saab T., M. Aguilera S, Cubillo A., Garcia-Carbonero R., Limon L., Rodriguez-Salas N., Tournigand C., Borg C., Raghav K., Finley G., Strickler J., Beier F., Salim S., Esser R., Liu E., Adrian S., Lopez-Lopez C.
JournalANNALS OF ONCOLOGY
Volume32
PaginationS136-S137
Date PublishedJUL
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2021.05.166